Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 31

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 31
---
 fact the offering of the Warrants,
the Placement Agent Warrants did not involve a public offering of securities.

The Securities Purchase Agreement contained customary
representations and warranties. The January 2025 Offering closed on January 30, 2025.

Pursuant to an engagement letter agreement between and H.C. Wainwright & Co., LLC dated August 30, 2024, as amended on September 3, 2024 and January 24, 2025 (the “Engagement Agreement”), the
Placement Agent acted as the Company’s exclusive placement agent in connection with the January 2025 Offering.

Pursuant to the terms of the Engagement Agreement,
the Company paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the January 2025 Offering
and a management fee equal to 1.0% of the aggregate gross cash proceeds in the January 2025 Offering. In addition, the Company paid for
certain non-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the
Placement Agent (or its designees) the Placement Agent Warrants to purchase up to 76,616 shares of our common stock. The Placement Agent
Warrants have an exercise price equal to $1.2763 per share and are exercisable upon issuance, or January 30, 2025, for twenty-four months
from the date of issuance, or January 30, 2027.

The Company received net proceeds of approximately
$804,346.40 from the January 2025 Offering, after deducting estimated offering expenses paid by the Company, including the Placement Agent
fees. The Company intends to use the net proceeds from the January 2025 Offering for general corporate purposes, including working capital.

Reverse Split

On November 6, 2024, our Board of Directors (“Board”), our Board approved a reverse stock split of our Common Stock at a split ratio ranging between 1:3 and 1:5 (the “Split”), as determined by the Board in its sole discretion. On November 6, 2024, a majority of the stockholders of the Company approved the Split. Our Board will evaluate and determine whether effecting the Split is necessary in the near future to ensure compliance with all applicable Nasdaq listing requirements for the continued listing of our Common Stock on The Nasdaq Stock Market LLC.

Amendment to 202